Rep. Lisa C. McClain Purchases Shares of Teleflex Incorporated (NYSE:TFX)

Key Points

• Representative Lisa C. McClain purchased shares of Teleflex Incorporated (NYSE:TFX) between $1,001 and $15,000 on July 16th, while also selling shares of multiple other companies in the same price range.
• Teleflex recently announced a quarterly dividend of $0.34 per share, with records on August 15th, representing an annualized dividend of $1.36 and a yield of 1.1%.
• Equities analysts have mixed ratings for Teleflex, with target price adjustments ranging from $130.00 to $173.00, indicating a consensus rating of "Hold" and an average target price of $141.57.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Teleflex Incorporated NYSE: TFX. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Teleflex stock on July 16th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Teleflex Stock Down 0.4%

NYSE:TFX traded down $0.50 on Friday, hitting $121.00. 322,158 shares of the company's stock traded hands, compared to its average volume of 797,540. The company has a current ratio of 2.41, a quick ratio of 1.44 and a debt-to-equity ratio of 0.42. Teleflex Incorporated has a 1 year low of $108.90 and a 1 year high of $249.90. The firm has a 50-day moving average price of $117.93 and a 200-day moving average price of $132.81. The company has a market cap of $5.35 billion, a PE ratio of 28.47, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08.

Teleflex (NYSE:TFX - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The company had revenue of $780.90 million for the quarter, compared to analysts' expectations of $771.53 million. During the same quarter in the previous year, the business posted $3.42 EPS. The business's revenue for the quarter was up 4.2% on a year-over-year basis. Equities analysts anticipate that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Friday, August 15th. Teleflex's payout ratio is 32.00%.

Analysts Set New Price Targets

Several equities analysts have weighed in on TFX shares. Royal Bank Of Canada lifted their target price on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a research note on Friday, August 1st. Wall Street Zen raised Teleflex from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Wells Fargo & Company lowered their target price on Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Morgan Stanley lowered their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research note on Monday, May 5th. Finally, Truist Financial lowered their price target on Teleflex from $140.00 to $137.00 and set a "hold" rating for the company in a research note on Monday, May 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $141.57.

Insider Buying and Selling

In related news, CEO Liam Kelly acquired 1,500 shares of the stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average price of $115.07 per share, for a total transaction of $172,605.00. Following the completion of the purchase, the chief executive officer owned 45,267 shares in the company, valued at approximately $5,208,873.69. The trade was a 3.43% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gretchen R. Haggerty bought 500 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were bought at an average cost of $114.75 per share, for a total transaction of $57,375.00. Following the transaction, the director directly owned 6,305 shares of the company's stock, valued at $723,498.75. This trade represents a 8.61% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 5,500 shares of company stock worth $633,590. 1.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Teleflex

Several large investors have recently made changes to their positions in TFX. State of Tennessee Department of Treasury boosted its holdings in shares of Teleflex by 7.6% during the 2nd quarter. State of Tennessee Department of Treasury now owns 17,466 shares of the medical technology company's stock worth $2,067,000 after buying an additional 1,233 shares during the period. Tidal Investments LLC increased its stake in shares of Teleflex by 26.2% in the second quarter. Tidal Investments LLC now owns 7,563 shares of the medical technology company's stock worth $895,000 after purchasing an additional 1,571 shares during the period. Man Group plc lifted its position in shares of Teleflex by 16.5% during the 2nd quarter. Man Group plc now owns 186,512 shares of the medical technology company's stock worth $22,076,000 after purchasing an additional 26,470 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Teleflex by 75.3% during the 2nd quarter. Lazard Asset Management LLC now owns 28,168 shares of the medical technology company's stock valued at $3,333,000 after purchasing an additional 12,099 shares during the period. Finally, HRT Financial LP grew its holdings in Teleflex by 143.1% in the 2nd quarter. HRT Financial LP now owns 61,101 shares of the medical technology company's stock valued at $7,231,000 after buying an additional 35,963 shares during the last quarter. Institutional investors own 95.62% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.